TRN 501
Alternative Names: TRN-501Latest Information Update: 02 Jul 2024
At a glance
- Originator SNLD
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Parkinson's disease
Most Recent Events
- 10 May 2024 Phase-I clinical trials in Parkinson's disease in Japan (Intranasal) (NCT06453551)